What You Need To Know Before You Buy Ostarine

Phase ll trial of Ostarine in Patients with Cancer-induced Muscle Wasting 

Muscle loss due to cancer starts early, leading to reduced physical ability and other harmful clinical outcomes. This phase 2 study, which was randomized, double-blind, and placebo-controlled, evaluated the effectiveness and safety of Ostarine, a selective androgen receptor modulator, for those with cancer. 

The team included males (over 45 years old) and female (postmenopausal) cancer subjects who were not obese and had lost at least 2% of their weight in the past 6 months. Participants were randomly divided in a 1:1:1 ratio, using a computer-generated list, block size three, and sorted by cancer type to take either 1 mg or 3 mg of Ostarine or a placebo once a day for up to 113 days. The study took place at oncology clinics in the US and Argentina. 

The main goal was to measure the change in total lean body mass from the beginning of the study, using dual-energy x-ray absorptiometry. Effectiveness analyses were conducted only on subjects who had a baseline and an assessment within 10 days before the study started, or first received Ostarine, and within 10 days of day 113 or the end of the study (evaluable efficacy population). 

Adverse effects and other safety measures were examined in the intention-to-treat (safety) population. This trial is registered with ClinicalTrials.gov under the number NCT00467844.

Out of 159 patients tested for safety (placebo: 52; Ostarine 1 mg: 53; Ostarine 3 mg: 54), 100 were included in the effectiveness analysis (placebo: 34; Ostarine 1 mg: 32; Ostarine 3 mg: 34). 

Both Ostarine groups showed notable increases in total lean body mass from the start to day 113 or the study’s end (Ostarine 1 mg: 1.5 kg on average, range: -2.1 to 12.6; Ostarine 3 mg: 1.0 kg on average, range: -4.8 to 11.5). The placebo group saw no significant change in total lean body mass (average: 0.02 kg, range: -5.8 to 6.7). 

None of the following adverse outcomes were considered related to the administration of Ostarine. Cancer growth (15% in the placebo group, 9% in the Ostarine 1 mg group, and 13% in the Ostarine 3 mg group), pneumonia (4% in both the placebo and Ostarine 1 mg groups, and 6% in the Ostarine 3 mg group), and fever with low white blood cell count (6% in the placebo group, 2% in the Ostarine 1 mg group, and none in the Ostarine 3 mg group). 

Ostarine’s effects on Muscle Wasting in Non-Small Cell Lung Cancer Patients (NSCLC) A Phase lll Trial Breakdown 

The study sought to assess the effectiveness and safety of Ostarine in promoting lean muscle mass in individuals with non-small cell lung cancer (NSCLC). 

The study began in May 2011 and completed in March 2013. It was conducted at multiple locations across the United States, Europe, South America, and Asia. 

The study enrolled 648 participants aged 18 years or older diagnosed with stage III or IV NSCLC who were starting first-line chemotherapy. Participants were randomized to receive either Ostarine or a placebo, in addition to their standard-of-care chemotherapy. 

The primary outcome measures (what the investigator considers the most important measures) included the following: 

Lean body mass (LBM) responder rate at Day 84, defined as the percentage of subjects with an increase in LBM of ≥1 kg from baseline. 

LBM refers to the weight of everything in the body except fat, including muscle mass, bones, organs, and water. The LBM responder rate at Day 84 measures the proportion of participants who experienced an increase in their LBM of at least 1 kilogram (≥1 kg) from their initial LBM measurement (baseline) 84 days after administration.

A higher LBM responder rate would indicate that a greater percentage of participants experienced a significant increase in their lean body mass during the study.

Stair climb power (SCP) responder rate at Day 84, defined as the percentage of subjects with an increase in SCP of ≥10% from baseline. 

SCP is a measure of the ability to climb stairs, which can be an indicator of overall physical strength and endurance, particularly in the lower body muscles. SCP is typically calculated by considering the time it takes to climb a specific number of stairs, subject’s body weight, and the height of the stairs.

The SCP responder rate at Day 84 measures the proportion of participants who experienced an increase in their SCP of at least 10% (≥10%) from their initial SCP measurement (baseline) after 84 days.

A higher SCP responder rate would indicate that a greater percentage of subjects experienced a significant improvement in their stair climb power during the study, suggesting a positive impact on physical function and performance.

The results show that 62.0% of subjects in the Ostarine group experienced a significant increase in their LBM, compared to only 37.2% of participants in the placebo group. 

Suggesting that Ostarine was more effective than the placebo in the study population, as a higher proportion of subjects in the Ostarine group experienced a significant increase in lean body mass. 

The results show that 49.5% of participants in the Ostarine group experienced a significant improvement in their SCP, compared to only 28.7% of subjects in the placebo group. 

Ostarine was more effective than the placebo in improving physical function and muscle performance in the study population, as a higher proportion of participants in the Ostarine group experienced a significant increase in stair climb power. 

The primary outcome measures showed promising results. Secondary outcome measures included overall survival, progression-free survival, response rate, safety, and quality of life. However, there was no statistically significant difference in overall survival between the two groups. 

In conclusion, the study demonstrated that Ostarine significantly improved LBM and SCP in patients with NSCLC receiving chemotherapy but did not show a significant impact on overall survival. 

Ostarine’s Clinical Conclusion 

In conclusion, Ostarine has a long history of preclinical and clinical phase 1,2, and 3 phase studies evaluating its efficacy and safety. 

As said before, Ostarine has been the most studied SARM to date.

The laboratory research on Ostarine suggests the potential for muscle wasting conditions and cancer. Ostarine shows its positive effects on lean muscle mass, bone density, and muscle blood supply. Further research and larger trials are needed to fully understand its long-term safety and effectiveness.

Conclusion Question: How Do Other SARMs Compare to Ostarine? 

From a scientific standpoint, Ostarine holds the best data, comparatively to any other completed phase l or ll trial involving the experimentation of SARMs. 

Its chemical structure and pharmacokinetics allow it to be of efficient use in a clinical setting. Offering a bioavailability and structure that works well within test subjects, it seems to have small amounts of adverse outcomes in completed trials. 

Studies prove that Ostarine had stronger clinical results when compared to other SARMs. Data suggested the Ostarine group In the study discussed previously “Ostarine and Ligandrol Improve Muscle Tissue in a Ovariectomized Rat Model” exhibited the most effect in a pre-clinical setting compared to LGD-4033.

Ostarine vs RAD140 is another commonly discussed SARMs comparison, as they are among the most popular SARMs with some of the most clinical research.

Although technically a growth hormone secretagogue (GHS) MK 677 has been applied within laboratory research use alone and in conjunction with other secretagogues. MK 677 appears to have the same rate of the desired outcome. However, MK 677 is limited to ONLY having an effect on the release of growth hormone from the pituitary gland and isn’t seen to have a dramatic effect on protein synthesis in subjects in a critical state, while Ostarine does. 

Furthermore, Ostarine has shown groundbreaking effects in patients with Non-small cell lung cancer (NSCLC). While the effect on the overall survival of test subjects was unaffected, the symptoms that give the disease its harsh nature were shown to dramatically decrease. Ostarine improved the overall state patients were in prior to administration. 

In conclusion, Ostarine is the most clinically studied compound out of all SARMs. Its ability has been tested on hundreds of subjects in both preclinical and clinical settings. For more information, here are 5 questions about SARMS on Quora and why research is ongoing.